Castelein Caley 4

What Happened

• Caley Castelein, a director of Whitehawk Therapeutics, was granted a derivative award covering 38,040 shares on June 12, 2026. The Form 4 records the acquisition price as $0.00 (total $0) and classifies the transaction as an award/grant rather than an open-market purchase or sale. The filing’s footnote identifies the award as an option subject to vesting based on continued service.

Key Details

• Transaction date: 2026-06-12; Form 4 filed: 2026-06-15.
• Reported price: $0.00 per share; reported value: $0 (derivative award).
• Shares owned after transaction: not specified in this Form 4.
• Footnote: The shares/options vest 100% on the earlier of (i) the one-year anniversary of the grant (June 12, 2027) or (ii) the day before the next annual meeting of stockholders, provided the reporting person remains a Service Provider under the 2021 Equity Incentive Plan.
• Filing timeliness: Form shows the filing date of 6/15 for a 6/12 grant; the report does not state a tardiness designation.

Context

• This is a compensation-related award (a derivative/option grant), not a cash purchase or sale—so it reflects standard director compensation rather than an immediate bullish or bearish market action.
• Because vesting is time- and service-based, the award is not immediately exercisable or saleable; its future value will depend on service continuation and any applicable exercise terms and company stock performance.